55 Da second-generation sulfonylurea usually administered at a daily dose of 2
Pharmacology Mechanism of Action Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites
Glipizide/metformin hydrochloride fixed combination: Upper respiratory
Glipizide is an N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl
Tips Response/effectiveness Interactions 1
The prescription of metformin is contraindicated in DKD because it undergoes renal excretion 9 and its most serious adverse effect is the development of lactic acidosis, although this is a very rare occurrence, Therefore, glipizide is the SU of choice in patients with CKD
The metabolism and excretion of glipizide may be slowed in patients with impaired renal function (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, and DOSAGE AND ADMINISTRATION)
The Chemical Abstracts name of glipizide is 1-cyclohexyl-3-[[p-[2-(5-methylpyrazine-carboxamido)ethyl]phenyl]sulfonyl]urea
Renal and Hepatic Disease: The metabolism and excretion of glipizide may be slowed in patients with impaired renal and/or hepatic function
Renal impairment: The metabolism and excretion of glyburide may be slowed in patients with renal impairment and its active metabolites may accumulate in advanced renal insufficiency (Snyder 2004)
The more common side effects that can occur with glipizide tablets include: low blood sugar
There is no information on the pharmacokinetics of glipizide in elderly patients
The risk of hypoglycaemia can be mitigated by avoiding sulfonylureas Glipizide comes as tablets and extended-release (long-acting) tablets to take by mouth
The chemical name for glipizide is 1-cyclohexyl-3-[[p-[2-(5-methylpyrazinecarboxamido) ethyl] phenyl] sulfonyl] urea
Glipizide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes
Renal and Hepatic Disease: The metabolism and excretion of glipizide may be slowed in patients with impaired renal and/or hepatic
5 to 5 mg orally once a day before first main meal of the day
Renal and Hepatic Disease: The metabolism and excretion of glipizide may be slowed in patients with impaired renal and/or hepatic
Time to Peak
Renal and Hepatic Disease: The metabolism and excretion of glipizide may be slowed in patients with impaired renal and/or hepatic
It is completely absorbed after oral administration and has a rapid onset of action, but the duration of its hypoglycaemic effect is shorter than that of glibenclamide
If hypoglycemia should
Glipizide also does not need dose adjustment in severe and moderate renal disease and can be used safely
A